Aspirin in stroke prevention in nonvalvular atrial fibrillation and stable vascular disease: an era of new anticoagulants

References

• Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation117(4), e25–e146 (2008).
   PubMed Web of Science ®Google Scholar
• Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation110(9), 1042–1046 (2004).
   PubMed Web of Science ®Google Scholar
• The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N. Engl. J. Med.323(22), 1505–1511 (1990).
   PubMed Web of Science ®Google Scholar
• Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation84(2), 527–539 (1991).
   PubMed Web of Science ®Google Scholar
• EAFT (European Atrial Fibrillation Trial) study group. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet342(8882), 1255–1262 (1993).
   PubMed Web of Science ®Google Scholar
• Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK. Lancet1(8631), 175–179 (1989).
   PubMed Web of Science ®Google Scholar
• Ezekowitz MD, Bridgers SL, James KE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med.327(20), 1406–1412 (1992).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation (CAFA) Study. J. Am. Coll. Cardiol.18(2), 349–355 (1991).
   PubMed Web of Science ®Google Scholar
• Wann LS, Curtis AB, January CT et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation123(1), 1041–1023 (2011).
   Google Scholar
• Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J.31(19), 2369–2429 (2010).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, O’Donnell M, Yusuf S et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am. Heart J.159, 348–353 (2010).
   PubMed Web of Science ®Google Scholar
• Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb. Haemost.106(3), 528–538 (2011).
   PubMed Web of Science ®Google Scholar
• Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation – friend or foe? Thromb. Haemost.104(1), 45–48 (2010).
   PubMed Web of Science ®Google Scholar
• Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA285, 2864–2870 (2001).
   PubMed Web of Science ®Google Scholar
• Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest137(2), 263–272 (2010).
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GY, Hansen ML et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ342, d124 (2011).
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schema for stroke in 79,884 atrial fibrillation patients in general practice. J. Thromb. Haemost.9(1), 39–48 (2011).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.361, 1139–1151 (2009).
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med.365(10), 883–891 (2011).
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJ et al. The ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med.365(11), 981–992 (2011).
   PubMed Web of Science ®Google Scholar
• Roskell NS, Lip GY, Noack H, Clemens A, Plumb JM. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb. Haemost.104(6), 1106–1115 (2010).
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Oldgren J, Yang S et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY trial. Circulation125(5), 669–676 (2012).
   PubMed Web of Science ®Google Scholar
• Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch. Intern. Med. doi:10.1001/archinternmed.2011.1666 (2012) (Epub ahead of print).
   PubMedGoogle Scholar
• Gorin L, Fauchier L, Nonin E et al. Anti-thrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score = 1. Thromb. Haemost.103(4), 833–840 (2010).
   PubMed Web of Science ®Google Scholar
• Lee BH, Park JS, Park JH, Park JS, Kwak JJ, Hwang ES. The effect and safety of the anti-thrombotic therapies in patients with atrial fibrillation and CHADS score 1. J. Cardiovasc. Electrophysiol.21(5), 501–507 (2010).
   PubMed Web of Science ®Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: anti-thrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann. Intern. Med.146(12), 857–867 (2007).
   PubMed Web of Science ®Google Scholar
• Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with nonvalvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst. Rev.4, CD0019 (2005).
   Google Scholar
• Sato H, Ishikawa K, Kitabatake A et al. Japan Atrial Fibrillation Stroke Trial Group. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke37(2), 447–451 (2006).
   PubMed Web of Science ®Google Scholar
• Healey JS, Hart RG, Pogue J et al. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE-W). Stroke39(5), 1482–1486 (2008).
   PubMed Web of Science ®Google Scholar
• Lane DA, Kamphuisen PW, Minini P, Büller HR, Lip GY. Bleeding risk in atrial fibrillation patients: The AMADEUS study. Chest140(1), 146–155 (2011).
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom JW, Ng J et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann. Intern. Med.155(9), 579–586 (2011).
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet367, 1903–1912 (2006).
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation124, 1573–1579 (2011).
   PubMed Web of Science ®Google Scholar
• Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb. Haemost.107(3), 584–589 (2011).
   PubMed Web of Science ®Google Scholar